Flow cytometric DNA analysis has the potential to significantly enhance the clinical care of tumour patients in the future. The majority of these research have looked at aneuploidy and % S phase as indicators of disease recurrence and survival. These two DNA analysis parameters have been correlated with traditional diagnostic parameters for the tumour being studied, such as cytology (e.g., lung and uterine), state of differentiation (e.g., prostate), pathological tumour grade or stage (e.g., bladder, prostate, and lymphoma), number of involved lymph nodes (e.g., breast cancer), and others, in several excellent studies. This topic was given its own volume in the Annals of the New York Academy of Science (Vol. 468, 1986). "Generalizations cannot be made when using flow cytometric DNA analysis to clinical decision making," as Merkel et al. (1987) pointed out.
An aberrant DNA histogram's prognostic significance for an individual patient must be determined using the relevant data set for that tumour type." The nonclinical reader should consult McNicol's outstanding review to put flow cytometry in its right context within the traditional diagnostic environment, which includes immunohistochemical and ultrastructural studies as well as clinical and biochemical results (1987).
No comments:
Post a Comment